Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824–33.

Article  PubMed  Google Scholar 

Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.

Article  Google Scholar 

Fukayama M, Ushiku T. Epstein-Barr virus-associated gastric carcinoma. Pathol Res Pract. 2011;207(9):529–37.

Article  CAS  PubMed  Google Scholar 

Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol. 2015;46(4):1421–34.

Article  CAS  PubMed  Google Scholar 

Fukayama M, Abe H, Kunita A, Shinozaki-Ushiku A, Matsusaka K, Ushiku T, et al. Thirty years of Epstein-Barr virus-associated gastric carcinoma. Virchows Arch. 2020;476(3):353–65.

Article  PubMed  Google Scholar 

Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 2012;72(14):3445–50.

Article  CAS  PubMed  Google Scholar 

Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017;23:4441–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Beek J, Zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004;22(4):664–70.

Article  PubMed  Google Scholar 

Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63(2):236–43.

Article  PubMed  Google Scholar 

Liu X, Liu J, Qiu H, Kong P, Chen S, Li W, et al. Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015;15:782.

Article  PubMed  PubMed Central  Google Scholar 

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.

Article  CAS  PubMed  Google Scholar 

Gao P, Lazare C, Cao C, Meng Y, Wu P, Zhi W, et al. Immune checkpoint inhibitors in the treatment of virus-associated cancers. J Hematol Oncol. 2019;12(1):58.

Article  PubMed  PubMed Central  Google Scholar 

Xie T, Zhang Z, Zhang X, Gong J, Qi C, Li J, Shen L, Peng Z. Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study. J Immunother. 2020;43(4):139–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corallo S, Fuca G, Morano F, Salati M, Spallanzani A, Gloghini A, et al. Clinical behavior and treatment response of epstein-barr virus-positive metastatic gastric cancer: implications for the development of future trials. Oncologist. 2020;25(9):780–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, et al. The impact of molecular subtype on efficacy of chemotherapy and checkpoint inhibition in advanced gastric cancer. Clin Cancer Res. 2020;26(14):3784–90.

Article  CAS  PubMed  Google Scholar 

Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, et al. A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol. 2011;68(4):913–21.

Article  PubMed  Google Scholar 

Sun J, Chen X, Gao P, Song Y, Huang X, Yang Y, et al. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis. Dis Markers. 2016;2016:7862469.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27–40.

Article  CAS  Google Scholar 

Cho J, Kang MS, Kim KM. Epstein-Barr virus-associated gastric carcinoma and specific features of the accompanying immune response. J Gastric Cancer. 2016;16(1):1–7.

Article  PubMed  PubMed Central  Google Scholar 

Kuzushima K, Nakamura S, Nakamura T, Yamamura Y, Yokoyama N, Fujita M, et al. Increased frequency of antigen-specific CD8(+) cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma. J Clin Invest. 1999;104(2):163–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang F, Liu ZY, Xia YY, Zhou C, Shen XM, Li XL, et al. Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer. Oncol Lett. 2015;10(6):3411–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roh CK, Choi YY, Choi S, Seo WJ, Cho M, Jang E, et al. Single patient classifier assay, microsatellite instability, and Epstein-Barr virus status predict clinical outcomes in stage II/III gastric cancer: results from CLASSIC trial. Yonsei Med J. 2019;60(2):132–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baek DW, Kang BW, Kim JG. The predictive value of epstein-barr virus-positivity in patients undergoing gastrectomy followed by adjuvant chemotherapy. Chonnam Med J. 2018;54(3):173–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23(4):565–78.

Article  CAS  PubMed  Google Scholar 

Kim JH, Ryu MH, Park YS, Ma J, Lee SY, Kim D, et al. Predictive biomarkers for the efficacy of nivolumab as >/= 3(rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. BMC Cancer. 2022;22(1):378.

Article  PubMed  PubMed Central  Google Scholar 

Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2009;24(3):354–65.

Article  PubMed  Google Scholar 

Kim HS, Beom SH, Jung M, Choi YY, Son T, Kim H, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget. 2016;7(28):44608–20.

Article  PubMed  PubMed Central  Google Scholar 

Koh J, Lee KW, Nam SK, Seo AN, Kim JW, Kim JW, et al. Development and validation of an easy-to-implement, practical algorithm for the identification of molecular subtypes of gastric cancer: prognostic and therapeutic implications. Oncologist. 2019;24(12):e1321–30.

Article  PubMed  PubMed Central  Google Scholar 

Hissong E, Zhang P, Zhou XK, Young G, Klimstra DS, Shia J, Fernandes H. Gastric carcinomas with lymphoid stroma: an evaluation of the histopathologic and molecular features. Am J Surg Pathol. 2018;42(4):453–62.

Article  PubMed  Google Scholar 

Matsunou H, Hori H, Ikeda T, Sasaki K, Vamamichi N. Characteristics of Epstein–Barr virus-associated gastric carcinoma with lymphoid stroma in Japan. Cancer. 1996;77:1998–2004.

Article  CAS  PubMed  Google Scholar 

Harn HJ, Fau CJ, Wang MW, Fau WM, Ho LI, Fau HL, Lee HS, Lee Fau HS, Chiang JH, Fau CJ, Lee WH, et al. Epstein-Barr virus-associated gastric adenocarcinoma in Taiwan. Hum Pathol. 1995;26:0046–8177.

Article  Google Scholar 

Huber M, Pavlova B, Muhlberger H, Hollaus P, Lintner F. Detection of the Epstein-Barr virus in primary adenocarcinoma of the lung with Signet-ring cells. Virchows Arch. 2002;441(1):25–30.

Article  CAS  PubMed  Google Scholar 

Park YS, Kook MC, Kim BH, Lee HS, Kang DW, Gu MJ, et al. A standardized pathology report for gastric cancer:2nd editon. J Gastric Cancer. 2023;23(1):107–45.

Article  PubMed  PubMed Central  Google Scholar 

Lim H, Park YS, Lee JH, Son DH, Ahn JY, Choi KS, et al. Features of gastric carcinoma with lymphoid stroma associated with Epstein-Barr virus. Clin Gastroenterol Hepatol. 2015;13(10):1738-44 e2.

Article  PubMed  Google Scholar 

Noh JH, Shin JY,